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Insulin resistance is a common feature of non-insulin-dependent diabetes mellitus (NIDDM)
and "diabetes susceptibility genes" may be involved in this abnormality. Two potential
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(GLUT-4). To elucidate whether structural defects in the IR and/or GLUT-4 could be a
primary cause of insulin resistance in NIDDM, we have sequenced the entire coding region
of the GLUT-4 gene from DNA of six NIDDM patients. Since binding properties of the IRs
from NIDDM subjects are normal, we also analyzed the sequence of exons 16-22 (encoding
the entire cytoplasmic domain of the IR) of the IR gene from the same six patients. When
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analysis of the GLUT-4 gene revealed that one patient was heterozygous for a mutation in
which isoleucine (ATC) was substituted for valine (GTC) at position 383. Consequently, the
GLUT-4 sequence at position 383 was determined in 24 additional NIDDM patients and 30
nondiabetic controls and all showed only the normal sequence. From these studies, we
conclude that the insulin resistance seen in the great majority of subjects with the common
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Abstract
Insulin resistance is a common feature of non-insulin-depen-
dent diabetes mellitus (NIDDM) and "diabetes susceptibility
genes" may be involved in this abnormality. Two potential can-
didate genes are the insulin receptor (IR) and the insulin-sensi-
tive glucose transporter (GLUTT4). To elucidate whether struc-
tural defects in the IR and/or GLUT4 could be a primary
cause of insulin resistance in NIDDM, we have sequenced the
entire coding region of the GLUT4 gene from DNAof six
NIDDM patients. Since binding properties of the IRs from
NIDDMsubjects are normal, we also analyzed the sequence of
exons 16-22 (encoding the entire cytoplasmic domain of the
IR) of the IR gene from the same six patients. Whencompared
with the normal IR sequence, no difference was found in the
predicted amino acid sequence of the IR cytoplasmic domain
derived from the NIDDMpatients. Sequence analysis of the
GLUT-4 gene revealed that one patient was heterozygous for a
mutation in which isoleucine (ATC) was substituted for valine
(GTC) at position 383. Consequently, the GLUT-4 sequence at
position 383 was determined in 24 additional NIDDMpatients
and 30 nondiabetic controls and all showed only the normal
sequence. From these studies, weconclude that the insulin resis-
tance seen in the great majority of subjects with the common
form of NIDDMis not due to genetic variation in the coding
sequence of the IR ft subunit, nor to any single mutation in the
GLUT4gene. Possibly, a subpopulation of NIDDMpatients
exists displaying variation in the GLUT-4 gene. (J. Clin. In-
vest. 1991. 88:1323-1330.) Key words: insulin receptor gene -
insulin resistance * insulin-sensitive glucose transporter
(GLUT4) gene * non-insulin-dependent diabetes mellitus * po-
lymorphism * sequencing
Introduction
Although non-insulin-dependent diabetes mellitus (NIDDM)'
is a heterogeneous pathophysiologic disorder, insulin resis-
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tance is a characteristic feature in essentially all subjects with
established hyperglycemia (1). Furthermore, recent evidence
indicates that in high-risk populations, individuals destined to
develop NIDDMare insulin resistant before the onset of clini-
cally apparent hyperglycemia (2, 3). In the prediabetic state,
increased insulin secretion compensates for the insulin resis-
tance, but when this compensating mechanism fails, hypergly-
cemia ensues. This suggests that insulin resistance is a primary
defect of etiologic importance in the pathogenesis of this dis-
ease. The cellular basis for this insulin resistance has received
considerable attention (4), and most studies have indicated
that postbinding defects are the predominant cause of the de-
crease in insulin action (5, 6). Thus, insulin receptor signaling
is impaired in NIDDMand decreased insulin receptor auto-
phosphorylation and tyrosine kinase activity has been reported
in fat (7, 8), liver (9), and skeletal muscle (10), as well as other
tissues (1 1). In addition, a decrease in insulin-stimulated glu-
cose transport activity has been consistently observed in skele-
tal muscle and adipocytes from NIDDMsubjects (4, 12). Since
the insulin-sensitive glucose transporter (GLUT-4) is responsi-
ble for the preponderance of insulin-mediated glucose uptake
in these tissues (1 3, 14), the reported decrease in glucose trans-
port activity must involve impaired GLUT-4 function. Interest-
ingly, although the adipocyte glucose transporter number is
decreased in NIDDM(4), recent studies have reported normal
total skeletal muscle GLUT-4 levels (15). Since skeletal muscle
is the major site of in vivo glucose disposal, this indicates that
impaired recruitment of GLUT-4 to the cell surface or de-
creased GLUT-4 intrinsic activity accounts for the component
of insulin resistance owing to the glucose transport defect in
NIDDM.
NIDDMhas a strong genetic component (16, 17), raising
the possibility that insulin resistance is inherited in this dis-
order. Given that defects in both insulin receptor and GLUT-4
functions have been identified in this condition, it seemed rea-
sonable to speculate that a molecular alteration in the genes
encoding one or both of these proteins might exist. To assess
this question, we have sequenced the exons comprising the
entire GLUT-4 coding sequence in six NIDDM subjects,
whose clinical and metabolic characteristics were typical for
type II diabetic subjects. In these same patients we have se-
quenced the exons (16-22) that encode the cytoplasmic do-
main of the insulin receptor (18). Wechose this latter ap-
proach, rather than analyzing the entire receptor gene, because
the functions of the cytoplasmic domain (signaling and kinase
activity) are impaired in NIDDM(4), whereas properties of the
ectodomain (binding) are normal (10, 19, 20).
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Methods
Chemicals. The following were purchased: avian myeloblastosis virus
reverse transcriptase, T7 RNApolymerase from Promega Corp., Ma-
dison, WI; Taq polymerase from Perkin-Elmer Cetus, Norwalk, CT;
T4 polynucleotide kinase, deoxynucleotides, nick-translation kit from
Bethesda Research Laboratories, Gaithersburg, MD; dideoxynucleo-
tides, Sephadex G-50 from Pharmacia, Inc., Piscataway, NJ; Centricon
100 from Amicon Corp., Danvers, MA; Sequenase from United States
Biochemical Corp., Cleveland, OH; perfect match from Strategene
Inc., La Jolla, CA; [y-32P]ATP (6,000 Ci/mmol), [32P]dCTP (3,000
Ci/mmol) from Dupont NewEngland Nuclear, Boston, MA; all other
chemicals used were primarily from Sigma Chemical Co., St.
Louis, MO.
Subjects. The clinical and metabolic characteristics of the six
NIDDMsubjects are presented in Table I. Subject 2 is Mexican Ameri-
can and the other five subjects are Caucasian. All six subjects had un-
equivocal fasting hyperglycemia and displayed insulin resistance as as-
sessed by the euglycemic glucose clamp technique. Based on fasting
glucose and insulin levels, body mass index, age, and clinical character-
istics they represent "typical" NIDDMsubjects. An additional group
of 24 NIDDMpatients and 30 nondiabetic controls was used in the
allele-specific polymerase chain reaction (PCR) screening studies as
described below. All nondiabetics were confirmed as normal on the
basis of standard 75-g oral glucose tolerance tests and each of the addi-
tional 24 NIDDM subjects had fasting plasma glucose levels > 9.7
mmol/liter.
Preparation of genomic DNAfrom the patient's blood. Genomic
DNAwas isolated from peripheral blood according to standard proce-
dures (21).
Enzymatic amplification of genomic DNA. Five different sets of
primers (Table II) were used to amplify 11 exons and adjacent introns
of the GLUT-4 gene by PCR(22). By using sets of primers as described
by Seino et al. (23), the regions representing exons 16-22 of the insulin
receptor gene were amplified using standard conditions of PCR.
Briefly, each reaction was performed in a volume of 25 Al containing 50
mMKCI, 10 mMTris-Cl (pH 8.3), 1 mMMgCI2, 100 Mg/ml gelatin;
100MMeach of dATP, dGTP, dCTP, and dTTP; 1 MMof each oligonu-
cleotide primer, 0.25 Mg of Hind III-digested genomic DNA; 1.25 U
Taq DNApolymerase; and 1 U perfect match. After initial denatur-
ation at 94°C for 10 min, the samples were subjected to 40 cycles of
amplification with an automated thermal cycler (Ericomp, Inc., San
Diego, CA); annealing at 48-55°C (depending on the melting tempera-
ture of the primer) for 2 min, extension at 72°C for 3 min and denatur-
ation at 94°C for 1 min. The upstream oligonucleotide of each set of
primers contained a T7 phage promoter sequence at its 5' end for direct
sequence analysis by avian myeloblastosis virus reverse transcriptase as
described (24).
Direct sequence analysis using single-stranded DNAas a template.
In some instances, it was very difficult to analyze the nucleotide se-
quence of certain regions of the amplified DNAby reverse transcrip-
tase. These regions include nucleotides 3529-3543 (exon 2), 3759-
3777 (exon 3), 4272-4386 (exon 4b), and 5210-5234 (exon 7) of the
Table I. Clinical and Metabolic Characteristics of Subjects with
NIDDM
Subject Body mass Fasting Fasting Glucose
No. Age Sex index glucose insulin disposal rate*
yr kg/M mmol/liter pmol/liter mg/kg per min
1 52 M 40.6 15.0 143.5 6.30
2 63 M 23.0 14.1 50.2 ND
3 57 F 29.7 13.8 287.0 4.58
4 67 F 28.8 17.3 71.7 4.53
5 55 F 28.8 15.7 50.2 7.42
6 67 M 26.3 17.6 64.6 5.54
ND, not determined.
* These values represent the steady-state glucose disposal rates during
glucose clamp studies at an insulin infusion rate of 300 mU/M2per
min. The mean (±SE) normal glucose disposal rate in our laboratory
is 11.5±1.3 mg/kg per min and in NIDDMpatients is 5.2±0.7 mg/kg
per min.
GLUT-4 gene and nucleotides 12733-12932 of the insulin receptor
exon 22 (23). In these cases, the sequence was determined by sequenase
using single-stranded DNA as the template (25). Briefly, single-
stranded DNAwas synthesized according to the protocol described
above for the first PCR(23), except for three changes. First, to amplify
one strand of DNAselectively, only one of the two oligonucleotide
primers (either the upstream or the downstream primer) was included.
Secondly, amplified DNA(5 ng) synthesized in the first PCRwas used
as template. Finally, the second PCRreaction was carried out in a
I00-Ml volume instead of 25 md. 5 ,l of the second PCRproduct was run
on a 1.5% agarose gel to document the size of the amplified product to
be sequenced. Subsequently, the rest of the amplified DNAsolution
was extracted with an equal volume of chloroform. Single-stranded
DNAwas separated from the oligonucleotides and deoxynucleotide
triphosphates by precipitation with ammonium chloride and isopro-
panol (25) followed by filtration through a Centricon 100 membrane
according to the manufacturer's instruction (Amicon Corp.). The re-
tentate (45 md) was dried in a concentrator (Speed Vac) and dissolved in
5 Ml of water immediately before use in the DNAsequencing reaction.
End-labeling of the sequencing primer (40 pmol) was performed
according to standard procedures (21). The 32P-labeled oligonucleo-
tides were purified by chromatography through Sephadex G-50 (21).
The eluant (100 LI) was dried in a concentrator (Speed Vac, Savant
Instruments Inc., Farmingdale, NY) and dissolved in 4.8 M1 of sterile
water. Sequencing reactions using Sequenase were carried out accord-
ing to the protocol used by Kadowaki et al. (26).
Allele-specific PCRamplification. For amplification of specific al-
leles by PCR, we used the method described by Sarkar et al. (27). The
sets of primers used for amplification of either the normal or mutant
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Table IL Oligonucleotide Primers for Amplification of HumanGLUT-4 Exons by the Polymerase Chain Reaction
Fragment Size of PCR
No. Upstream primer Downstream primer Exon fragment
bp
A Y-GAGACTCCAGGATCGGTTC 5'-CTGCGCCTGCGCAGGAACC 1 224
(2162-80) (2344-62)
B 5'-GGTTCCATGTGACATGCTG 5'-AAGCCCACCATATTCTCCA 2, 3, 4a, 4b 980
(3493-3511) (4431-49)
C 5'-CAGAAGGGCTGAGTGACCT 5'-CAGGTGCTAGCAAGATGAG 5 294
(4461-79) (4713-31)
D 5'-CTGGCTTCCTCTCAGGTCC 5'-ACAGAGACTCACAGGACCA 6, 7, 8 839
(4729-47) (5526-44)
E 5Y-AAGGCCTCAACTGGATTCT 5'-GAGAGGGTTAAAGTGCTGC 9,10 1075
(5952-70) (6985-7003)
To amplify each fragment, two oligonucleotide primers were used: an upstream primer with the sequence derived from the sense strand and a
downstream primer with the sequence derived from the antisense strand. Numbers in parenthesis indicate location of the primer in the human
GLUT-4 gene sequence. Since each upstream primer at its 5' end contained a 23-bp-long T7 phage promoter sequence (TAATACGACTCA-
CTATAGGGAGA)to facilitate direct sequence analysis, the size of the individual PCRfragment was calculated after the addition of 23 bp. The
nucleotide positions of the individual exons in the GLUT-4 gene sequence are as follows: exons 1 -- 2225-2257; 2 -* 3535-3651; 3
3763-3935; 4a -- 4028-4152; 4b -- 4276-4379; 5 -* 4507-4669; 6 -- 4775-4962; 7 -- 5125-5229; 8 -* 5378-5479; 9 -* 5995-6198; and 10 -
6716-6919.
The downstream primers were designed to recognize only the normal
(A) or mutant (A') sequences by modifying the 3' nucleotides of A' to
correspond to the detected point mutation. Primer sets A and A' di-
rected amplification of a 194-base pair (bp) GLUT4 allele-specific
fragment. Primer set A only amplifies PCRfragments from alleles with
normal sequences corresponding to the regions of the primers, and set
A' amplifies PCR fragments only from alleles with mutations corre-
sponding to the 3' nucleotides of the downstream primer. The PCRwas
carried out according to standard conditions as described earlier at an
annealing temperature of 500C for 2 min. As an internal positive con-
trol, all reaction mixtures contained an additional primer set
(5t-'2537AGTCACCCAGGACGTGTCC12555-3'; 5Y- 3044GAACGATC_
TCTGAACTCCA'326-3') for exon 22 of the insulin receptor. This
primer set directs amplification of a 507-bp fragment.
Results
To elucidate whether structural defects in the insulin receptor
and/or insulin-responsive glucose transporter could be a pri-
mary cause of insulin resistance in NIDDM, we have se-
quenced the entire coding region of the GLUT-4 gene and
exons 16-22 of the insulin receptor gene from white blood
cell-derived DNAfrom six NIDDMpatients.
Insulin receptor gene. Using genomic DNAas a template
and oligonucleotides complementary to introns flanking each
of the exons (23), we used PCRcatalyzed by Taq DNApoly-
merase to amplify exons 16-22 of the insulin receptor gene.
These exons encode the entire cytoplasmic domain of the re-
ceptor (18). The nucleotide sequence of the amplified DNA
was then determined directly from the PCRmixture as de-
scribed in the Methods section. When the sequences of exons
16-22 from the six NIDDMsubjects were compared to the
previously published normal insulin receptor gene sequence
(18), no difference in the predicted amino acid sequence was
observed. At nucleotide position 3045 (corresponding to the
third nucleotide of codon 972, according to the numbering by
Ullrich et al. [28]), one patient was heterozygous for a silent
polymorphism. Codon 972 was TACand TAT (both Tyr) and,
thus, this polymorphism did not change the amino acid se-
quence (data not shown).
GLUT-4 gene. The human GLUT-4 gene has been isolated
and completely characterized by Bell et al. (13). The gene spans
a region of 8,000 bp on the short arm of chromosome 17 and is
composed of 11 exons and 10 introns (13). Using the known
sequence of the GLUT-4 gene as a guide, we selected five pairs
of primers (Table II) to amplify 224-, 980-, 294-, 839-, and
1 ,075-bp segments that include all 11 exons together with their
adjacent splice acceptor and donor sites. Using genomic DNA
as a template, the DNAamplification observed with these five
primer pairs is very specific and analysis of the amplified DNA
Figure 1. Amplification
std A B C D E std of the five fragments
containing the 11 exons
3054- of the GLUT-4 gene by
1636 - the PCR. Photograph of
1018- the ethidium bromide-
506,517w stained agarose gel of
396 _ the PCRproducts is344-
298- shown. The amplified
2201 fragments (A-E) are run201
in each lane as indi-
cated. Fragments A, B,
C, D, and E contain exon 1; exons 2, 3, 4a and 4b; exon 5; exons
6-8; and exons 9 and 10, respectively. Lanes marked std. contain
DNAstandards. 5 gl of each PCRreaction was separated by electro-
phoresis on 1.5% agarose gel in Tris-acetate buffer. The DNAstan-
dard used a 1 kb DNAladder from Bethesda Research Laboratories.










Figure 2. Partial nucleotide sequences of sense strand of GLUT-4
exon 9 from one of the six NIDDMsubjects, compared to control.
There are two bands (G and A) at nucleotide position 1292 (lane 2)
in NIDDMpatient 4 instead ofjust Gas in the normal subject (lane 1).
by gel electrophoresis indicated that little nonspecific priming
occurred (Fig. 1). The nucleotide sequences of the five PCR-
amplified fragments were determined as described in the Meth-
ods section. In five of the patients the predicted amino acid
sequence was identical to the published normal sequence (29).
The other subject (no. 4, Table I) was heterozygous for a sub-
stitution in the GLUT-4 sequence. This patient (no. 4) displays
both A and Gat nucleotide position 1292 (Fig. 2), correspond-
ing to codon 383 in exon 9. This leads to an isoleucine (ATC)
for valine (GTC) substitution in the fifth extracellular loop of
the GLUT-4 protein (Fig. 3). This sequence difference was con-
firmed on three separate sequencing gels derived from three
separate PCR amplifications. At nucleotide position 535
(corresponding to the third nucleotide of codon 130 [29]), two
patients were heterozygous and one subject was homozygous
for a silent nucleotide polymorphism. Codon 130 was AAC
and AAT (both Asn) and thus, this polymorphism did not
change the amino acid sequence (data not shown).
The valine -- isoleucine substitution is conservative and
Table III, which shows the sequence of GLUT- 1, -2, -3, and -5
at codon 383, reveals leucine at position 383 in GLUT-l and
isoleucine in GLUT-5. To further assess the potential signifi-
cance of mutation in NIDDM, we analyzed DNAfrom 24
additional NIDDMpatients and 30 nondiabetic subjects for
the presence of this substitution by allele-specific PCRamplifi-
cation. This method involves the use of PCRoligonucleotide
primer sets that amplify either the normal or mutant allele (30).
As can be seen in Fig. 4, both the normal (A) and mutant (A')
allele-specific primer sets amplify a GLUT-4 DNAfragment of
194 bp (lanes I and 2) from the genomic DNAof the patient
(no. 4) who was heterozygous for the Val383 -- Ile383 mutation.
In the 30 control and 24 additional NIDDMsubjects, PCR
amplification of the 194-bp fragment occurred only with the
normal allele primer set (A); lanes 3 and 4 show the results in
representative subjects. The primer set for insulin receptor
exon 22 gave rise to a 507-bp fragment in all samples, demon-
strating that the absence of mutant GLUT-4 fragments was not
due to a failure of the PCR.
Discussion
In patients with established NIDDMa variety of characteristic
metabolic defects exist. Amongthese are insulin resistance, in-
creased hepatic glucose production, and impaired pancreatic f:
cell function (1). The disease is clearly heterogeneous, and it
remains unproven which of these defects is primary. However,
a number of studies have examined "prediabetic" individuals
from high-risk populations and have found that insulin resis-
tance can be demonstrated before the development of hypergly-
cemia and in the absence of the other metabolic defects (2, 3,
31-33). These studies include first-degree relatives of NIDDM
subjects (31), identical twins of NIDDMsubjects (32), and sub-
jects from ethnic groups at high risk for NIDDM(33), such as
Pima Indians (2, 3). In the later population group, studies have
shown that insulin resistance is inherited and predates the on-
set of hyperglycemia. The above-mentioned studies, as well as
others (34), establish the strong genetic contribution to the de-
velopment of NIDDM as well as the importance of insulin
resistance.
In the current studies, we have focused our attention on the
insulin receptor gene and the gene for the insulin-sensitive glu-
cose transporter (GLUT-4) as candidate genes. The results rep-
resent the first sequence data available in NIDDM of the
GLUT-4 gene and, except for single case studies (35-37), of the
insulin receptor gene.
Insulin receptor. Insulin binding to the a-subunit triggers
activation of the tyrosine autophosphorylation/kinase activity
of the cytoplasmic domain of the A subunit which is felt to be
essential for many, if not all, of insulin's bioeffects (38, 39). A
modest decrease in receptor number exists in various tissues
Table III. Comparison of Partial Amino Acid Sequences between GLUT-4 of NIDDMSubjects and Different
HumanFacilitative Glucose Transporters
Subject Amino acid GLUT-4 from
No. codon No. GLUT-I GLUT-2 GLUT-3 GLUT-4 GLUT-5 NIDDMsubject
4 383 TyrLeuSer TyrValSer PheValCys TyrValSer Tyr leSer TyrILeSer
Amino acid number is according to human GLUT-4 as described by Fukumoto et al. (29) and indicate the position of the amino acid (under-
lined) substituted.
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Figure 3. Modified model for the exon-intron organization of the insulin-sensitive human glucose transporter (GLUT-4) gene. Adapted from the
model originally proposed for the ancestral facilitative glucose transporter gene by Bell et al. (13). The amino acids encoded by each of the 11
exons in the GLUT-4 gene are indicated by circles. 12 putative membrane-spanning domains are numbered MI -M 12 and are shown as rectan-
gles. A black circle indicates the position of the amino acid in GLUT-4 (383 according to numbering by Fukumoto et al. [29]), where the NIDDM
subject was heterozygous for a conservative amino acid replacement.
from NIDDMsubjects, but no alterations in the function of the
a subunits with respect to binding affinity or specificity have
been described (1). On the other hand, studies have consis-
tently shown a decrease in the receptor kinase activity in
NIDDMpatients (7-10). Although these kinase defects are re-
versible with weight reduction (40) and do not exist in fibro-
blasts cultured from NIDDMpatients (41), there could be a
genetic alteration in the insulin receptor rendering it suscept-
able to a functionally adverse post-translational change.
Since the binding functions of the insulin receptor are pre-
served in NIDDM, whereas kinase activity and signaling are
impaired, we restricted our studies to an analysis of the nucleo-
tide sequence of exons 16-22 of the insulin receptor gene.
These exons encode the entire cytoplasmic domain of the re-
ceptor protein including the kinase domain and other putative
signaling elements (18).
In all six patients, the sequence of the insulin receptor cyto-
plasmic domain was entirely normal. Thus, no evidence for a
genetic alteration leading to a change in the primary structure
of the insulin receptor was found. These findings, coupled with
a recent report that the full-length insulin receptor sequence
was normal in an NIDDMpatient (35), lead to the conclusion
that variations in the coding sequence of the insulin receptor
gene do not underlie the insulin resistance in the great majority
of NIDDMpatients. These results are also consistent with two
recent reports demonstrating a normal insulin receptor se-
quence in two diabetic Pima Indians (36, 37). It should be
pointed out that our results for both the insulin receptor and
GLUT-4 genes relate only to alterations in the coding se-
quences; the possibility of regulatory defects in the flanking
regions or deletion of an entire allele are not elucidated by our
studies.
Although our studies demonstrate that most NIDDMpa-
tients have a normal insulin receptor sequence, they do not
exclude the possibility that a small subset of patients with the
NIDDM phenotype have mutations in the insulin receptor
gene as a primary cause of their insulin resistance. Indeed, it is
quite likely that this is the case, although this probably ac-
counts for only a very small percentage of NIDDMpatients.
Thus, most patients with genetic forms of extreme insulin resis-
tance (type A insulin resistance, leprechaunism, Rabson Men-
denhall syndrome, etc.) are homozygotes or compound hetero-
zygotes for insulin receptor gene mutations. However, many
family members of these patients are simple heterozygotes, and
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Figure 4. Identification of normal and mutant GLUT-4 gene alleles in
NIDDMand normal subjects by the allele-specific PCR. Lanes I and
2 represent results in the patient heterozygous for the mutation, Val"3
- Ile383, and lanes 3 and 4 and 5 and 6 show representative results
from 24 additional NIDDMpatients and 30 nondiabetic subjects. As
an internal positive control, all reaction mixtures contained an addi-
tional primer set for the insulin receptor exon 22 that directed the
amplification of a 507-bp fragment. Genomic DNAwas isolated from
the peripheral blood of normal or NIDDMsubjects and PCRwas
performed as described in Methods using either the normal (A) (lanes
1, 3, and 5) or mutant (A') (lanes 2, 4, and 6) allele-specific primer
sets. Both primer sets directed the amplification of a 194-bp GLUT-4
allele-specific fragment and the mutant (A') primer set is designed to
detect the Ile383 variant.
in some cases the amino acid substitutions behave as dominant
negative mutations producing clinically significant insulin resis-
tance and sometimes diabetes. The phenotype of these hetero-
zygous family members is indistinguishable from NIDDM, par-
ticularly when the diabetes is discovered in later years. Possi-
bly, mutations such as these, when coupled with other acquired
abnormalities, such as obesity or ,3 cell dysfunction, produce
the NIDDMsyndrome and these kinds of heterozygous pa-
tients comprise the minimal estimate of the proportion of the
NIDDMpopulation associated with genetic mutations in the
insulin receptor gene.
Insulin-sensitive glucose transporter (GLUT-4). At least
five human glucose transporter species exist, displaying tissue
specific distribution. An insulin-regulatable glucose trans-
porter (GLUT-4) is uniquely expressed in muscle and adipose
tissue and accounts for the majority of insulin-stimulated glu-
cose transport ( 1 3, 14). Evidence exists to indicate that under
most physiologic circumstances the glucose transport step is
rate-limiting for overall in vivo glucose uptake (42). Conse-
quently, defects in glucose transport could be mechanistically
important to the in vivo insulin resistance in NIDDM. Indeed,
decreased rates of glucose transport have been widely reported
in adipocytes isolated from NIDDMsubjects (43). Most likely,
this is due to a reduced number of adipocyte GLUT-4 proteins
as well as decreased intrinsic activity of the transporters (4).
Skeletal muscle is responsible for 80-90% of insulin-stimulated
glucose uptake in vivo, and decreased in vitro glucose transport
has been reported in skeletal muscle from NIDDMsubjects
(44). These findings indicate that impaired glucose transport is
an important factor in the insulin resistance of NIDDM. How-
ever, in skeletal muscle, total cellular GLUT-4 levels (15), as
well as GLUT-4 mRNA(1 5) are normal in NIDDM. This indi-
cates that the decreased skeletal muscle glucose transport in
NIDDM is due to impaired recruitment (translocation) of
GLUT-4 transporters to the cell surface, a decrease in GLUT-4
intrinsic activity, or both. Given these findings plus the genetic
contribution to NIDDM, a primary defect in GLUT-4 struc-
ture seemed possible.
To assess this hypothesis, we have used PCRand direct
sequencing to amplify and sequence all 1 GLUT-4 exons (1 3)
from genomic DNAderived from six NIDDMsubjects. Our
results show that the GLUT-4 gene sequence was entirely nor-
mal in five of the six patients. One subject (no. 4) was heterozy-
gous for an A for Gmutation at nucleotide position 1292 lead-
ing to an isoleucine for valine substitution at codon 383 which
is in the fifth extracellular loop of the GLUT-4 protein (Fig. 3).
However, this is a structurally conservative substitution and
among the five human glucose transporter species, two
(GLUT- 1 and GLUT-50 already contain leucine (GLUT-1)
and isoleucine (GLUT-5) rather than valine at this position.
Since functional studies of transfected GLUT-4 cDNAscan
be problematic (44), we elected to pursue whether this substitu-
tions were significant in the etiology of NIDDM, by analyzing
DNAfrom an additional 24 NIDDMpatients and 30 nondia-
betic subjects. Allele-specific PCRamplification was used to
detect the presence of this substitution, and these additional
subjects showed only wild-type sequence at this position. Thus,
of the 60 NIDDMalleles analyzed, the frequency of the poly-
morphism identified was only one in 60 and it was not detected
in 30 nondiabetic subjects. From this, we conclude that this
specific genetic variant is uncommonand could only represent
a very small subset of the NIDDMpopulation. Given the low
frequency of this variant in the NIDDMgroup, studies in a
greatly expanded number of normals would be necessary to
determine whether its frequency is lower in normal versus
NIDDMsubjects.
The simplest interpretation of our data is that substitutions
in GLUT-4 are unusual in NIDDM and, therefore, do not
contribute to this disease in the great majority of NIDDMpa-
tients. However, we should also point out that although our
results provide evidence that no single mutation in the GLUT-
4 gene exists in a high proportion of NIDDMsubjects, we did
identify one substitution among our six subjects. This raises the
theoretical possibility that GLUT-4 gene mutations exist in a
small, but significant, subgroup of NIDDMpatients, but that
no single mutation will be common. Insofar as any GLUT-4
substitution is functionally significant, it could have impor-
tance to the NIDDMstate.
If inherited structural defects in the insulin receptor and
GLUT-4 genes are not the primary cause of cellular insulin
resistance in most NIDDMsubjects, then what defects might
be involved? Insulin action is obviously a complex process in-
volving multiple sequential steps. Our data would indicate
that, if a commongenetic defect in the insulin action cascade
exists, it is located at a step(s) between the insulin receptor and
GLUT-4. Since the total amount of skeletal muscle GLUT-4
protein is normal in NIDDM(15), it is reasonable to propose
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that a defect in recruitment of transporters to the cell surface
exists. This implies a postreceptor signaling abnormality in this
aspect of insulin action. Since not all aspects of insulin action
are equally resistant in NIDDM, it is possible that such a defect
lies in one or more proteins involved in the arm of postreceptor
insulin signaling related to glucose metabolism. Perhaps
NIDDM is multigenic and subgroups of patients will display
genetic defects in different proteins, in aggregate accounting for
the insulin resistance in NIDDM, consistent with the heteroge-
neous nature of this disease.
Note added in proof. Based on preliminary data reported in
abstract form (1991. Diabetes. 40:158A), a valine for methio-
nine mutation at GLUT-4 position 126 was initially identified
in one of our patients. However, subsequent experiments
showed the sequence to be normal in this patient.
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